Abcuro

Breakthrough Therapies for Autoimmune Diseases & Cancer

Wilkins, Jeffrey

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among

 READ MORE

H. Jeffrey Wilkins, MD

Chief Medical Officer

x

H. Jeffrey Wilkins, MD

Chief Medical Officer

Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his M.D. from Temple University School of Medicine and his B.S. from Bucknell University.

Subramanyam, Janaki

Janaki (Jana) Subramanyam is Vice President, Head of Regulatory Affairs at Abcuro. Jana is an experienced regulatory affairs professional having worked on small molecule and biologic development programs across rheumatology, nephrology, neurology, and psychiatry for more than twenty years. Her regulatory drug development expertise spans clinical, nonclinical, manufacturing, quality, post marketing advertising, and promotional activities.

 READ MORE

Janaki M. Subramanyam

VP, Head of Regulatory Affairs

x

Janaki M. Subramanyam

VP, Head of Regulatory Affairs

Janaki (Jana) Subramanyam is Vice President, Head of Regulatory Affairs at Abcuro. Jana is an experienced regulatory affairs professional having worked on small molecule and biologic development programs across rheumatology, nephrology, neurology, and psychiatry for more than twenty years. Her regulatory drug development expertise spans clinical, nonclinical, manufacturing, quality, post marketing advertising, and promotional activities. Prior to joining Abcuro, Jana was the Head of Regulatory Affairs at Allena Pharmaceuticals, Inc. where she helped develop two assets for rare metabolic diseases. Jana also held leadership roles in regulatory affairs at FORUM Pharmaceuticals, Lantheus Medical Imaging, and AMAG Pharmaceuticals. She received her M.S. in microbiology from Ohio University and her B.S. in microbiology and biochemistry from Bombay Universit

Searle, Stephen

Stephen A. Searle

Senior Program Manager

x

Stephen A. Searle

Senior Program Manager

Hwang, Ella

Ella Hwang

Senior Director, Quality

x

Ella Hwang

Senior Director, Quality

Shen, Yuyi

Yuyi Shen, PhD

Sr. Director of PD,
Manufacturing & Supply Chain

x

Yuyi Shen, PhD

Sr. Director of PD,
Manufacturing & Supply Chain

Gattemier, David

David J. Gattermeir

Director of Medical Writing

x

David J. Gattermeir

Director of Medical Writing

Reyes, Armando

Armando Reyes

Associate Clinical Director

x

Armando Reyes

Associate Clinical Director

Ward, Antonio

Antonio Ward, PhD

Senior Scientist

x

Antonio Ward, PhD

Senior Scientist

Rozzo, Aldo

Aldo Rozzo, PhD, DVM

Lab Manager

x

Aldo Rozzo, PhD, DVM

Lab Manager

Motschwiller, Ricky

Richard Motschwiller

Controller

x

Richard Motschwiller

Controller

McClain, Michael

Michael McClain

Clinical Trial Manager

x

Michael McClain

Clinical Trial Manager

LeMessurier, Hugo

Hugo LeMessurier

Director, Abcuro Pty Ltd

x

Hugo LeMessurier

Director, Abcuro Pty Ltd

Jiang, Lusi

Lusi Jiang

Senior Accountant

x

Lusi Jiang

Senior Accountant

Jaeker, Christoph

Christoph Jaeker

VP, Business Development & Strategy

x

Christoph Jaeker

VP, Business Development & Strategy

Hoffer, LaDonna

LaDonna Hoffer

Senior Director, Operations

x

LaDonna Hoffer

Senior Director, Operations

Chartienitz, Brett

Brett Chartienitz

IT Operations Manager

x

Brett Chartienitz

IT Operations Manager

Escobar , Jorge

Jorge Escobar

VP, Clinical Operations

x

Jorge Escobar

VP, Clinical Operations

Cui, Crystal

Crystal Cui

Senior Program Manager

x

Crystal Cui

Senior Program Manager

Borbas, Dave

Dave Borbas

Research VP,
Head of Data Management

x

Dave Borbas

Research VP,
Head of Data Management

Anderson, Jeff

Jeff Anderson

Office Manager

x

Jeff Anderson

Office Manager

Courtemanche, Kate

Kate Courtemanche is the Chief Development Officer of Abcuro. She is an industry leader with extensive drug development expertise in recombinant proteins and vaccines, as well as lentiviral and adeno-associated virus vectors, and oligonucleotides. Kate’s experience spans many therapeutic areas, including oncology, neurology, ophthalmology, infectious disease, autoimmune disease, stem cell therapy, gene therapy, and coagulation

 READ MORE

Kate Courtemanche

Chief Development Officer

x

Kate Courtemanche

Chief Development Officer

Kate Courtemanche is the Chief Development Officer of Abcuro. She is an industry leader with extensive drug development expertise in recombinant proteins and vaccines, as well as lentiviral and adeno-associated virus vectors, and oligonucleotides. Kate’s experience spans many therapeutic areas, including oncology, neurology, ophthalmology, infectious disease, autoimmune disease, stem cell therapy, gene therapy, and coagulation disorders. With 30 years’ experience driving the advancement of therapeutic drugs from early pre-clinical assessment to commercial licensure globally, she brings extensive expertise in chemistry, manufacturing and controls management, integration of clinical operations, regulatory, preclinical to commercial requirements, and program management strategy and development. Kate has experience in multiple settings including large pharma, contract manufacturing, and emerging biotechnology companies. She is President of KVC Biopharma LLC, received her B.S.  from the University of Massachusetts, project management professional certification (P.M.P), and an M.B.A. from North Carolina State University.

Greenberg, Steven A.

Steven A Greenberg, M.D., M.S. is a founder of Abcuro and is the Chair of the Medical Advisory Board. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion

 READ MORE

Steven A. Greenberg, MD

Chief Scientific Advisor and
Chair, Medical Advisory Board

x

Steven A. Greenberg, MD

Chief Scientific Advisor and
Chair, Medical Advisory Board

Steven A Greenberg, M.D., M.S. is a founder of Abcuro and is the Chair of the Medical Advisory Board. Steve is a clinical neurologist at Brigham and Women’s Hospital, and Professor of Neurology at Harvard Medical School. His clinical and laboratory research focus involves translational medicine, inventing diagnostics including blood tests for dermatomyositis and inclusion body myositis, and therapeutics, including co-inventing a therapeutic monoclonal antibody for dermatomyositis currently in late-stage clinical trials. He has authored over 100 publications and served as Principal Investigator for multiple clinical trials, and is the founder of the non-profit research organization, the Inclusion Body Myositis Foundation. Steve received an A.B. degree in Mathematics from Princeton University, an M.S. degree in Medical Informatics from Massachusetts Institute of Technology, and an M.D. degree from Harvard Medical School through the Harvard-MIT Health Science and Technology Program.

Edwards, John

John Edwards brings over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals. He was involved in the development or commercialization of ten FDA-approved biologics and has had successful exits at eight of the ten biotech companies he helped to build, including Tilos Therapeutics, Siamab Therapeutics, Exonics Therapeutics, Adnexus Therapeutics, F-star Therapeutics,

 READ MORE

John Edwards

Executive Chair and Interim CEO

x

John Edwards

Executive Chair and Interim CEO

John Edwards brings over 30 years of experience in discovery, development, and global commercialization of biopharmaceuticals. He was involved in the development or commercialization of ten FDA-approved biologics and has had successful exits at eight of the ten biotech companies he helped to build, including Tilos Therapeutics, Siamab Therapeutics, Exonics Therapeutics, Adnexus Therapeutics, F-star Therapeutics, and Genetics Institute. He built a hematology therapeutic business that reached over $1 billion in annual revenue for Wyeth/Genetics Institute and was responsible for leading the development of the fastest biologic to progress from phase I to FDA approval. John started his career in research and development as one of the first employees at Genzyme. He received his M.B.A. from Boston University and his B.S. in Chemical Engineering from the University of Massachusetts at Amherst.

Deware, Patricia

Patricia Deware

VP, Finance and Planning

x

Patricia Deware

VP, Finance and Planning

Privacy Site Credits Terms of Use

© 2022 Abcuro